Kronos Bio (KRON) Competitors $0.69 +0.02 (+2.53%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KRON vs. PRME, INMB, TLSA, MOLN, ELDN, OGI, INBX, PRQR, HURA, and DMACShould you be buying Kronos Bio stock or one of its competitors? The main competitors of Kronos Bio include Prime Medicine (PRME), INmune Bio (INMB), Tiziana Life Sciences (TLSA), Molecular Partners (MOLN), Eledon Pharmaceuticals (ELDN), Organigram (OGI), Inhibrx (INBX), ProQR Therapeutics (PRQR), TuHURA Biosciences (HURA), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Kronos Bio vs. Prime Medicine INmune Bio Tiziana Life Sciences Molecular Partners Eledon Pharmaceuticals Organigram Inhibrx ProQR Therapeutics TuHURA Biosciences DiaMedica Therapeutics Prime Medicine (NYSE:PRME) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Do institutionals & insiders have more ownership in PRME or KRON? 70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 64.1% of Kronos Bio shares are owned by institutional investors. 23.5% of Prime Medicine shares are owned by insiders. Comparatively, 24.4% of Kronos Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in PRME or KRON? Prime Medicine received 9 more outperform votes than Kronos Bio when rated by MarketBeat users. However, 65.63% of users gave Kronos Bio an outperform vote while only 65.22% of users gave Prime Medicine an outperform vote. CompanyUnderperformOutperformPrime MedicineOutperform Votes3065.22% Underperform Votes1634.78% Kronos BioOutperform Votes2165.63% Underperform Votes1134.38% Do analysts recommend PRME or KRON? Prime Medicine presently has a consensus price target of $11.80, indicating a potential upside of 859.35%. Kronos Bio has a consensus price target of $1.63, indicating a potential upside of 136.19%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities research analysts plainly believe Prime Medicine is more favorable than Kronos Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86Kronos Bio 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media prefer PRME or KRON? In the previous week, Prime Medicine had 22 more articles in the media than Kronos Bio. MarketBeat recorded 22 mentions for Prime Medicine and 0 mentions for Kronos Bio. Prime Medicine's average media sentiment score of 0.02 beat Kronos Bio's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media. Company Overall Sentiment Prime Medicine Neutral Kronos Bio Neutral Which has more risk and volatility, PRME or KRON? Prime Medicine has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Is PRME or KRON more profitable? Prime Medicine has a net margin of 0.00% compared to Kronos Bio's net margin of -867.66%. Kronos Bio's return on equity of -64.55% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Kronos Bio -867.66%-64.55%-48.18% Which has stronger earnings and valuation, PRME or KRON? Kronos Bio has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$3.85M41.99-$198.13M-$1.61-0.76Kronos Bio$9.19M4.56-$112.67M-$1.07-0.64 SummaryPrime Medicine beats Kronos Bio on 11 of the 19 factors compared between the two stocks. Get Kronos Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRON vs. The Competition Export to ExcelMetricKronos BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.95M$6.50B$5.34B$8.42BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.489.1526.8519.72Price / Sales4.56252.36387.23121.26Price / CashN/A65.8538.2534.62Price / Book0.256.456.774.51Net Income-$112.67M$144.21M$3.23B$248.32M7 Day Performance-2.41%2.38%1.81%0.60%1 Month Performance-21.47%4.50%10.93%13.18%1 Year Performance-31.20%-2.75%17.15%7.39% Kronos Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRONKronos Bio2.4981 of 5 stars$0.69+2.5%$1.63+136.2%-34.2%$41.95M$9.19M-0.48100High Trading VolumePRMEPrime Medicine3.6988 of 5 stars$1.34+3.1%$13.14+880.8%-85.5%$175.76M$3.85M-0.65234Trending NewsAnalyst ForecastAnalyst RevisionINMBINmune Bio1.9559 of 5 stars$7.64+9.6%$22.80+198.4%-29.4%$175.60M$14,000.00-3.5010Gap UpTLSATiziana Life Sciences0.9519 of 5 stars$1.50-4.5%N/A+73.2%$175.27MN/A0.008Gap UpMOLNMolecular Partners1.9586 of 5 stars$4.28+4.4%$12.00+180.4%+10.6%$172.81M$4.97M-1.99180Earnings ReportAnalyst RevisionGap UpELDNEledon Pharmaceuticals2.1643 of 5 stars$2.87-0.7%$12.50+335.5%+1.9%$171.86MN/A-1.4310News CoveragePositive NewsAnalyst UpgradeAnalyst RevisionOGIOrganigram0.2685 of 5 stars$1.28+8.5%N/A-30.2%$171.31M$166.12M-3.37860High Trading VolumeINBXInhibrx1.906 of 5 stars$11.71+4.7%N/A-61.6%$169.51M$200,000.000.00166PRQRProQR Therapeutics3.1983 of 5 stars$1.59-1.2%$8.75+450.3%-9.5%$167.29M$18.91M-4.97180HURATuHURA BiosciencesN/A$3.82-4.3%$12.67+231.6%N/A$166.86MN/A0.00N/ANews CoverageEarnings ReportAnalyst RevisionDMACDiaMedica Therapeutics1.5002 of 5 stars$3.83+4.6%$8.00+108.9%+35.9%$164.14MN/A-6.8420Analyst RevisionGap Down Related Companies and Tools Related Companies PRME Competitors INMB Competitors TLSA Competitors MOLN Competitors ELDN Competitors OGI Competitors INBX Competitors PRQR Competitors HURA Competitors DMAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRON) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KRON Stock Free KRON Stock Alerts